Zim Laboratories (NSE:ZIMLAB) Cash Flow from Operations: ₹0 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:ZIMLAB Zim Laboratories Ltd NSE:ZIMLAB
79 GF Score
Price ₹118.58
GF Value ₹102.67
Valuation Modestly Overvalued
! 8 Warning Signs
View Full Analysis

What is Zim Laboratories Cash Flow from Operations?

Zim Laboratories NSE:ZIMLAB -2.00% 79 Cash Flow from Operations is ₹0 Mil as of Mar. 2026. GuruFocus rates NSE:ZIMLAB with a GF Score™ of 79/100 and a GF Value™ of ₹102.67 (Modestly Overvalued). The stock has 8 warning signs investors should review.

Cash flow from operations refers to the cash brought in through a company's normal business operations. It is the cash flow before any investment or financing activities. It is the cash version of net income.

For the three months ended in Mar. 2026, Zim Laboratories's Net Income From Continuing Operations was ₹37 Mil. Its Depreciation, Depletion and Amortization was ₹51 Mil. Its Change In Working Capital was ₹0 Mil. Its cash flow from deferred tax was ₹0 Mil. Its Cash from Discontinued Operating Activities was ₹0 Mil. Its Asset Impairment Charge was ₹0 Mil. Its Stock Based Compensation was ₹0 Mil. And its Cash Flow from Others was ₹0 Mil. In all, Zim Laboratories's Cash Flow from Operations for the three months ended in Mar. 2026 was ₹0 Mil.


Zim Laboratories  (NSE:ZIMLAB) Cash Flow from Operations Explanation

For companies reported in indirect method, cash flow from operations contains six items:

1. Net Income From Continuing Operations:
Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Zim Laboratories's net income from continuing operations for the three months ended in Mar. 2026 was ₹37 Mil.

2. Depreciation, Depletion and Amortization:
Depreciation is a present expense that accounts for the past cost of an asset that is now providing benefits.
Depletion and amortization are synonyms for depreciation.
Generally:
The term depreciation is used when discussing man made tangible assets
The term depletion is used when discussing natural tangible assets
The term amortization is used when discussing intangible assets

Zim Laboratories's depreciation, depletion and amortization for the three months ended in Mar. 2026 was ₹51 Mil.

3. Change In Working Capital:
Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities. Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow.

Zim Laboratories's change in working capital for the three months ended in Mar. 2026 was ₹0 Mil. It means Zim Laboratories's working capital {id_Q12} from Dec. 2025 to Mar. 2026 .

4. Deferred Tax:
It is the cash flow generated from deferred tax.

Zim Laboratories's cash flow from deferred tax for the three months ended in Mar. 2026 was ₹0 Mil.

5. Cash from Discontinued Operating Activities:
Net cash from all of the entity's discontinued operating activities.

Zim Laboratories's cash from discontinued operating Activities for the three months ended in Mar. 2026 was ₹0 Mil.

6. Asset Impairment Charge:
It is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

Zim Laboratories's asset impairment charge for the three months ended in Mar. 2026 was ₹0 Mil.

7. Stock Based Compensation:
It is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Zim Laboratories's stock based compensation for the three months ended in Mar. 2026 was ₹0 Mil.

8. Cash Flow from Others:
These are cash differences caused by the change of inventory, accounts payable, accounts receivable etc. For instance, if a company pays its suppliers slower, its cash position will build up faster. If a company receives payments from its customers slower, its account receivables will rise, and its cash position will grow more slowly (or even shrink).

Zim Laboratories's cash flow from others for the three months ended in Mar. 2026 was ₹0 Mil.


Zim Laboratories Cash Flow from Operations Related Terms


Zim Laboratories Cash Flow from Operations Historical Data

* Premium members only.

The historical data trend for Zim Laboratories's Cash Flow from Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zim Laboratories Cash Flow from Operations Chart

Zim Laboratories Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cash Flow from Operations
Get a 7-Day Free Trial Premium Member Only Premium Member Only 492.06 381.68 162.78 411.55 495.34

Zim Laboratories Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cash Flow from Operations Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
NSE:ZIMLAB
79GF Score
Zim Laboratories Ltd NSE:ZIMLAB
Cash Flow from Operations is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Zim Laboratories Cash Flow from Operations Calculation

Cash flow from operations refers to the cash brought in through a company's normal business operations. It is the cash flow before any investment or financing activities. It is the cash version of net income.

Zim Laboratories's Cash Flow from Operations for the fiscal year that ended in Mar. 2026 is calculated as:

Zim Laboratories's Cash Flow from Operations for the quarter that ended in Mar. 2026 is:


Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Cash Flow from Operations of ₹0 Mil mean?
Zim Laboratories (NSE:ZIMLAB) has a Cash Flow from Operations of ₹0 Mil as of Mar. 2026. Cash Flow from Operations is the amount of cash earned or paid from standard business operations. View historical data for Zim Laboratories and its competitors.
Is Zim Laboratories' Cash Flow from Operations too high?
Zim Laboratories' current Cash Flow from Operations is ₹0 Mil. Overall, Zim Laboratories has a GF Score™ of 79/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Zim Laboratories' Cash Flow from Operations compare to ZTS and UTHR?
Zim Laboratories' Cash Flow from Operations of ₹0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow from Operations for a Drug Manufacturers company?
A good Cash Flow from Operations depends on the Drug Manufacturers industry context. However, Cash Flow from Operations should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow from Operations mean?
A high Cash Flow from Operations can signal that a stock is expensive relative to its fundamentals. Cash Flow from Operations is the amount of cash earned or paid from standard business operations. View historical data for Zim Laboratories and its competitors. Zim Laboratories's current Cash Flow from Operations is ₹0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zim Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Zim Laboratories (NSE:ZIMLAB) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹102.67, compared to a current price of ₹118.58 — trading 15.5% above its estimated fair value. The current Cash Flow from Operations is ₹0 Mil. Zim Laboratories' overall GF Score™ is 79/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow from Operations calculated?
Cash Flow from Operations is calculated from a company's financial statements. For Zim Laboratories (NSE:ZIMLAB), the current Cash Flow from Operations is ₹0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Zim Laboratories (NSE:ZIMLAB) Overvalued in 2026?

Based on GuruFocus' analysis, Zim Laboratories stock appears to be overvalued. The current stock price of ₹118.58 is trading 15.5% above its estimated GF Value™ of ₹102.67. GuruFocus considers Zim Laboratories to be Modestly Overvalued.

Key valuation signals for NSE:ZIMLAB:

  • Cash Flow from Operations: ₹0 Mil
  • GF Value™: ₹102.67 vs. price of ₹118.58 (15.5% above fair value)
  • GF Score™: 79/100 with 8 warning signs

No single metric tells the full story. See the NSE:ZIMLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Zim Laboratories Business Description

Other Exchanges 541400:India
Address Nelson Square, Chhindwara Road, Sadoday Gyan, Ground Floor, Opposite NADT, Nagpur, MH, IND, 440 013
Zim Laboratories Ltd is engaged in the manufacturing of formulation drugs and pre formulation ingredients in India and marketing and selling these within and outside India. It is engaged in manufacturing &wholesale of pharmaceutical products, market research and research & development activities. The Group is mainly engaged in the business of pharmaceuticals. It has presence in India and Outside India. The company generates majority of revenue from India. Its products are Oral Thin Films, Pre-formulations Intermediates, Finished Formulations.
79GF Score

Get the complete analysis for NSE:ZIMLAB

Cash Flow from Operations is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹118.58
Price
₹102.67
GF Value